Enterococcus species are common in nosocomial bloodstream infections and their incidence is rising. Although well recognized in several serious bacterial infections, the influence of appropriate antimicrobial therapy in enterococcal bacteraemia has not been fully settled.
Introduction
Bloodstream infections are major causes of mortality [1] . In the past decade Enterococcus spp. has become the third most common aetiological agent isolated in nosocomial bloodstream infections in the United States [2, 3] . In Denmark it rates fourth [4] . Reported mortality rates after enterococcal bacteraemia range from 19% to 48% [4] [5] [6] . It is generally accepted that enterococcal bacteraemia often occurs in patients with underlying illnesses [7] and the observed high mortality has been ascribed to this issue rather than to the intrinsic pathogenicity of the Enterococcus spp. Contrary to this belief, a study including patients with enterococcal bacteraemia and matched uninfected controls found a significant excess mortality attributed to Enterococcus spp. of 31% [8] . The rates of infective endocarditis in patients with enterococcal bacteraemia vary from 1% to 32% [9, 10] , thereby only accounting for a limited part of the mortality in enterococcal bacteraemia.
Inappropriate and delayed antibiotic therapy has been reported in several large cohort studies to be associated with excess mortality [11] . The issue of antimicrobial therapy in enterococcal bacteraemia is controversial: a few studies have found no decrease in mortality with appropriate antibiotic treatment [12, 13] . In contrast, prospective studies have demonstrated a significantly better outcome with appropriate antimicrobial therapy, both for vancomycin-resistant (VRE) and high level gentamicin-resistant (HLGR) Enterococcus spp [14, 15] .
The aim of the study was to determine whether administration of inappropriate empirical antibiotics in enterococcal bacteraemia is an independent predictor of mortality, among other known and suspected risk factors.
Patients and methods

Study design and population
The study was conducted as a retrospective analysis of prospectively collected routine data at Rigshospitalet, Denmark, a 1120-bed tertiary care and reference facility with approximately 200 000 patients admitted during the 3-year study for a total of more than 1 100 000 admission days, and the largest national centre for solid organ transplantation in Denmark. All patients at our hospital with a positive blood culture for E. faecalis and E. faecium between 1 January 2002 and 15 January 2005 were assessed for eligibility. The study population was identified in January 2005 using the electronic log at the Department of Clinical Microbiology at Rigshospitalet. (http://www.rh.dk). Patients younger than 16 years and patients for whom date of death was missing were excluded from the analyses.
Identification and susceptibility testing
Blood cultures were performed using the BD/BACTEC/ 9000-system (Becton Dickinson, NJ, USA). Isolates were identified using API identification (BioMérieuxÔ, Marcy I'Etoile, France) and conventional biochemical reactions [16] . Susceptibility testing for E. faecalis and E. faecium was performed using agar diffusion (Statens-Serum-Institut, Copenhagen, Denmark) with Rosco Ò NeoSensitabs (Rosco Taastrop, Denmark). Zone diameter breakpoints for antibiotics used refer to the standards listed by the Swedish Reference Group for Antibiotics (http://www.srga.org) in combination with those listed by Rosco, Denmark. In cases with clinically suspected endocarditis, E-test Ò (BioMérieuxÔ) was performed for penicillin-G and gentamicin.
Notification of clinician
When a blood culture was positive for growth the physician in charge was notified and advised regarding antimicrobial chemotherapy and further diagnostic procedures. When E. faecalis/faecium was identified including a susceptibility pattern, a follow-up phone call concerning the patient's progress and definitive antimicrobial therapy was performed and a final written report sent to the relevant clinical department.
Data collection
Trained study team members reviewed the medical charts and extracted demographic data, and information about hospitalization dates and length, ward, co-morbidities, concomitant infections, patients' discharge diagnoses and clinical outcomes, including date of death, antibiotic prescription data, including dosage and number of treatment days of all administered antimicrobials, indwelling catheters, and vital status. Clinical and microbiological data were transferred from the original chart from the referring hospital to the chart at our hospital, and these data were recorded whenever possible into the database. All-cause mortality was registered at 30 days after the onset of bacteraemia in the national central register, where all deaths and emigrations are registered. Data concerning clinical characteristics (e.g. concomitant infections, sepsis, acute liver, and respiratory or renal failure) and number of positive blood cultures were recorded. The level of co-morbidity was measured using the Charlson¢s comorbidity score [17] . Biochemical data, obtained on the same day as the blood culture sample, were also collected and included in the analyses. The suspected source of infection was recorded from patients' charts. All data were entered into the database and marked as 'not cleared'. Another member of the study team quality assessed the data and data were then termed 'cleared'.
Permission for construction of the database was obtained from the Danish Data Protection Agency.
Definitions and criteria
Cultures were regarded as contamination and excluded from analysis in the absence of (i) a sepsis diagnosis or (ii) signs of localized infection and clinical data supporting infection [18] .
All patients with a non-enterococcus blood stream infection within ±3 days of the blood culture with Enterococcus spp. were counted as 'polymicrobial'. The appropriateness of the administered antibiotics for use against co-pathogens in polymicrobial bloodstream infections was assessed as for therapy against enterococci (see below). Three episodes of polymicrobial blood stream infection (co-infection with candida spp.) were not included in the mortality analysis because data on antifungal therapy for these three were incomplete.
Appropriate antimicrobial therapy was defined when: (i) the antimicrobial therapy was instituted no later than the day when the blood culture sample was positive for growth (median 1 day; IQR, 1-2); (ii) the spectrum of the administered antibiotics covered the susceptibility of the Enterococcus spp. and was an accepted treatment for enterococcal infection (see below); (iii) the dosage was adequate according to national recommendations (Danish national guidelines published in the relevant years by a committee of peers from the Danish Medical Association); dosages could be adjusted to renal function, weight, etc.; (iv) no contraindications or relevant interactions with other drugs existed; and (v) antimicrobials were not discontinued before at least 6 days of treatment. Patients who died before a full 6-day treatment of appropriate antimicrobials was given, were maintained in the group of appropriate antimicrobials for analysis, when antibiotics were administered until the date of death.
Antimicrobials regarded as acceptable for enterococcal bacteraemia were, whenever in vitro: active ampicillin (recommended 2 g three to four times daily), penicillin G (recommended two MIE TID) or piperacillin/tazobactam (recommended 4 g/0.5 g TID), vancomycin (recommended 1 g BID), linezolid (recommended 600 mg BID) and teicoplanin (recommended loading 400 mg BID, followed by 200 mg BID). Whenever possible (patient tolerance/allergy, resistance, etc.), betalactam therapy was preferred.
The date the positive blood culture was sampled (day 0) was used to calculate the precise date of death until 30 days after the onset of bacteraemia.
Statistics
Comparisons between continuous variables were performed using the Student t-test (normal) or the Mann-Whitney Utest (non-parametric). Fischer¢s exact-test was used to compare categorical variables.
To determine the independent risk factors for mortality, the stepwise and best subset approach was used to build a forward censored logistic regression model with a cut-off of p <0.1 in the univariate analysis. In the final model, the Hosmer-Lemeshow assessment of the goodness-of-fit of the model had a p-value of 0.82. The AUC for the ROC curve of the identified predictors was: ICU admittance, 0.68 (95% CI, 0.59-0.77); platelets <150 · 10 9 /L, 0.66 (0.58-0.75); nonadequate antimicrobials administered, 0.60 (0.50-0.69); age >60 years, 0.58 (0.49-0.67); chronic liver insufficiency, 0.55 (0.45-0.65). A two-tailed p value £0.05 was considered statistically significant. Analyses of data were performed using SPSS version 15.0 for Windows (Chicago, IL, USA) and GraphPad software (San Diego, CA, USA).
A sample size was calculated to detect an odds ratio of 2.2 (Sample Size v. 2.04, CreoStat Software, Frö lunda, Sweden) [19, 20] with a type 1 error risk of 0.05 and a power of 0.8. The frequency of the endpoint in the population, based on other bacteraemia studies, was set at 0.25, frequency of risk variable (inappropriate antibiotics) in the population was set at 0.30, and the multiple correlation of covariates (rho2) was set at 0.09. Using these estimates, the calculated sample size was 179 patients.
Results
Bacteraemic episodes
A total of 324 patients with E. faecalis or E. faecium bacteraemia were evaluated for eligibility. Forty-two patients were excluded because their age was below 16 years (n = 28) or they were lost to follow up (n = 14), 79 were excluded due to incomplete data regarding antibiotic prescription, and seven patients with central lines were suspected of having contamination, leaving 196 patients in the study (Fig. 1) . Polymicrobial infections with a clinically significant pathogen occurred in 14% (28/196) of the cases (Staphylococcus aureus 4%, Klebsiella spp. 18%, E. coli 29%, Enterobacter spp. 14%, Pseudomomas spp. 14% and other spp. 21%). Co-infection with coagulase-negative staphylococci was present in 14% of enterococcal bacteraemias.
Baseline characteristics
Appropriate antimicrobial therapy as defined for our study was administrated in 74% (146/196) of the cases with enterococcal bacteraemia. The two groups did not differ concerning age, gender and ICU stay ( Table 1 ). All but one of the 28 patients with polymicrobial bacteraemia received appropriate antimicrobials for the secondary pathogen. The one patient (30-day survivor) not receiving appropriate therapy had a co-infection with clostridium and bacteroides spp. and received inappropriate therapy for both bacteroides and enterococcus spp.
Of the nine cases with endocarditis, dual therapy was administered in seven (betalactam + aminoglycoside in three, betalactam + vancomycin in two, vancomycin + linezolid in one, and betalactam + rifampicin + moxifloxacin in one). The combinations were chosen according to the MIC determined for the specific drug and according to possible side-effects, primarily on renal function. The median Charlson index [17] of co-morbidity of two reflects a patient population with a high degree of chronic co-morbidity. However, patients receiving inappropriate antimicrobial therapy were more often without any co-morbidity (OR 0.44, 0.21-0.92), and were less represented in the highest Charlson score (Table 1 ).
E. faecalis and E. faecium were evenly distributed. No VRE strains were identified in the study.
The majority (78%) of enterococcal blood stream infections were nosocomially acquired.
Mortality
The mortality rate for enterococcal bacteraemia at 30 days was 26% (50/196). The administration of appropriate antimicrobial therapy was associated with a decreased mortality (OR 0.39, 0.19-0.78) when compared with patients with inappropriate antimicrobial therapy ( Table 1) .
A survival curve for patients receiving appropriate resp. inappropriate antibiotics is shown in Fig. 2 .
The mortality rate for patients with E. faecium bacteraemia was 36%, compared with 18% for patients with E. faecalis bacteraemia (OR 2.63, 1.36-5.09). Of the 87 patients with E. faecalis, the mortality in those who received a beta-lactam drug for at least 6 days (or until death) was 17.1%, compared with 19.2% for those who received other classes of drugs covering enterococci (i.e. glycopeptides or linezolide) for a similar period of time.
Multivariable regression analysis
The variables included in the regression model analysis for mortality at 30 days are shown in Table 2 . Using forward censoring with a p-limit of 0.1, seven variables were entered into the multivariable logistic regression model.
Four independent risk factors were identified: administration of appropriate antibiotics was inversely associated with death (OR 0.33, 0.14-0.79), ICU admission was a risk factor for death (OR 4.2, 1.7-10), as was thrombocytopenia (OR 3.9, 1.6-9.3) and chronic liver failure (OR 3.3, 1.1-10).
Discussion
Benefit of appropriate antibiotic therapy
The study demonstrated that the administration of inappropriate antimicrobial therapy to patients with enterococcal bacteraemia is an independent risk factor for mortality.
Only one study has previously addressed this issue in a comparably large cohort [14] ; however, our study was conducted in a geographical region without VRE strains, thereby stressing the importance of appropriate antibiotics in serious enterococcal disease, irrespective of susceptibility pattern [15] . Despite verified bloodstream infection with E. faecium or E. faecalis, 26% of the patients in this study did not receive appropriate antimicrobial therapy for at least 6 consecutive days after diagnosis, a rate comparable with the rate found in other cohort studies of bacteraemia patients [11, 21, 22] . In suspected sepsis, antimicrobials active against enterococci are not always added empirically, a practice questioned by our results.
Mortality rates and co-morbidity
The high mortality rates for enterococcal bacteraemia (26%) have been found elsewhere; a recent Danish study [23] reported an 18% mortality rate from bacteraemia at 30 days and 25% at 90 days. Vergis et al. [12, 13] found a 14-day mortality rate of 19% in 398 cases of enterococcal bacteraemia.
The high co-morbidity rate in our population may in part explain the high total mortality rates, but not the lower mortality rate observed in patients receiving appropriate antimicrobial therapy, thus indicating a substantial effect of enterococcal infection on the prognosis of the patient. The appropriate and inappropriate antimicrobial groups were evenly distributed in the study with regard to co-morbidities and enterococcal species. An unpublished E. coli bacteraemia study at Rigshospitalet, conducted by the authors during the same time period, found similar co-morbidity and mortality rates (data not shown).
The retrospective design of the study, and the exclusion of 28% (79/282) of the cases due to incomplete antimicrobial therapy data, could be considered limitations. While the sample size does not allow for definitive conclusions, a relevant sample of patients was included in congruence with the power calculation.
In conclusion, the use of inappropriate antibiotics in the first 6 days following a case of enterococcal bacteraemia was an independent risk factor for mortality. In addition to the clinical implications, these results improve our understanding of the nature of the enterococcal bloodstream infection. It would be worthwhile to verify these results in a large, prospective study. Variables with p <0.1 in the univariate analysis were included in the multivariate model. a Thrombocytopenia was defined as a platelet count of £150 · 10 9 /L. OR, odds ratio. Hosmer-Lemeshow statistics for goodness of fit, p 0.82. Area under the receiver operating characteristics curve for the above-found independent predictors of 30-day all-cause mortality: ICU-admittance, 0.68 (95% CI, 0.59-0.77); platelets <150 · 10 9 /L, 0.66 (0.58-0.75), non-adequate antimicrobials administered, 0.60 (0.50-0.69); age >60 years, 0.58 (0.49-0.67); chronic liver insufficiency, 0.55 (0.45-0.65). Univariate analyses were initially performed for the following variables (apart from the above): sepsis, peritonitis, endocarditis, renal failure (acute and chronic), solid tumour cancer, haematological cancer, organ transplantation, polymicrobial blood stream infection, ‡2 blood culture sets within ±3 days with enterococci, c-reactive protein ‡50 mg/L, site of infection (suspected clinically/ proven microbiologically): abdominal, indwelling catheter, urinary tract, wound, skin and soft tissue, lung, other/unknown. Using forward censoring with a pvalue cut-off of 0.1, only the variables displayed in this table were included in the final model. Using a p-value cut-off of 0.2 did result in entering six variables more in the multivariable model, but the same covariates were identified as independent, and with comparable OR as when using 0.1.
FIG. 2.
Kaplan-Meier curve survival with and without appropriate antibiotics.
